BOTTOM LINE
Annual screening of adults to detect proteinuria and prevent end-stage renal disease (ESRD) is not cost-effective unless directed only at high-risk groups (that is, those patients with diabetes and hypertension). Screening every 10 years beginning at the age 60 years, however, is highly cost-effective. (LOE=1b)